As a next-generation selective S1P receptor modulator, VELSIPITY® offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily ...

Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody targeting PD-1 and VEGF, has been granted its fifth Breakthrough Therapy ...

Many people who should be taking statins avoid them for fear of side effects. A large new study says most of those side ...

16-hour intermittent fasting torches real fat while 12 and 14-hour windows don't, according to an 8-week study comparing four ...

Moving gemcitabine/nab-paclitaxel to every-other-week dosing decreases infusion visits and may lessen cumulative toxicity, ...

Several fruits, hardy vegetables, warming spices, and other foods contain anti-inflammatory compounds that help reduce inflammation for better overall health.

Median overall survival differed significantly by race: 36.8 months for Black patients versus 48.4 months for White patients ...

OVATION 3 is IMUNON’s pivotal Phase 3 study of IMMN-001, an IL-12 gene-mediated immunotherapy, in women with advanced stage epithelial ovarian cancer. The study is supported with unprecedented overall ...

SOL-1 Phase 3 superiority trial results remain masked to dateSOL-1 data expected to be presented at the 49th Macula Society Annual Meeting Ocular ...

China’s National Medical Products Administration (NMPA) has granted regulatory approval for 2 next-generation ophthalmic ...

For people with depression who aren’t getting adequate relief from medication, new research suggests a high-fat, low-carb ...

Chamorro argued that the apparent difference in mortality likely reflects an "extremely low" event rate among control ...